No headlines found.
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
Business Wire (Mon, 25-Mar 4:01 PM ET)
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA by January 2025
Business Wire (Thu, 11-Jan 8:01 AM ET)
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Acorda Therapeutics trades on the NASDAQ stock market under the symbol ACOR.
As of March 28, 2024, ACOR stock price declined to $11.82 with 726 million shares trading.
ACOR has a market cap of $14.68 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ACOR stock traded as high as $127.20 and as low as $5.22.
The top ETF exchange traded funds that ACOR belongs to (by Net Assets): VXF, VTI.
ACOR has underperformed the market in the last year with a price return of +3.3% while the SPY ETF gained +33.8%. ACOR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -14.3% and -4.7%, respectively, while the SPY returned +10.2% and +1.8%, respectively.
ACOR support price is $11.05 and resistance is $12.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACOR stock will trade within this expected range on the day.